Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype - 09/08/11
Washington, DC, and Bethesda, Maryland
Abstract |
Background |
Psoriasis genetics researchers have utilized separate and widely differing survey instruments to capture clinical data to be utilized in genotype-phenotype studies, which make comparison and collaboration studies among these researchers difficult.
Objective |
The purpose of this study was to develop and validate a clinical survey instrument to facilitate future collaborative genotype-phenotype studies among psoriasis genetics researchers.
Methods |
The Delphi method was employed to obtain international consensus on components of the novel survey instrument. The survey was pretested for acceptability purposes, and then formally tested for reliability using 3 independent raters interviewing 48 subjects with psoriasis.
Results |
Data showed high or moderately high agreement for questions relating to place of birth (85% to 100% in agreement), family origin (κ = 0.48 -1.0), psoriasis history (κ = 0.66-1.0), patient medical history (κ = 0.76-1.0), distribution of lesions (κ = 0.73-1.0), precipitating factors (κ = 0.79-1.0), joint involvement (κ = 0.74-.91), and treatment history, including use of oral retinoids, methotrexate, and etanercept (κ = 0.73-1.0). Other parameters had lower degrees of agreement.
Limitations |
The time involved and the need for the rater to be a clinician with knowledge of psoriasis may preclude widespread use of this survey instrument.
Conclusion |
We developed a novel, reliable survey instrument that can be used to gather clinical information in a standardized manner from psoriasis patients participating in clinical and genetics research studies.
Le texte complet de cet article est disponible en PDF.Plan
Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. Conflicts of interest: None identified. |
Vol 54 - N° 6
P. 987.e1-987.e14 - juin 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?